Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 3Gastrointestinal 3Thoracic 2Gynecologic 2Genitourinary 2

Conditions

Uterine Cervical Neoplasms 8Ovarian Neoplasms 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Non-Small-Cell Lung 2Lung Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

pembrolizumab 35Paclitaxel 10Nivolumab 10Carboplatin 9atezolizumab 7Docetaxel 7Cisplatin 7Ipilimumab 5Gemcitabine 5Cyclophosphamide 5spartalizumab 4fludarabine 4Fluorouracil 4lenvatinib 3durvalumab 3cemiplimab 3avelumab 3Vorinostat 3Trastuzumab 3Oxaliplatin 3Leucovorin 3Immunoglobulin G 3Fulvestrant 3Cetuximab 3Bevacizumab 3zimberelimab 2tisotumab vedotin 2tislelizumab 2sargramostim 2aldesleukin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × tisotumab vedotin × Gynecologic × Clear all
NCT02001623 2021-12-29

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Seagen Inc.

Phase 1/2 Completed
195 enrolled 51 charts
GastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT03245736 2021-11-04

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Seagen Inc.

Phase 2 Completed
5 enrolled 8 charts
GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡